Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter clinical trial is to assess the clinical impact of dose
intensification performed very early during treatment in a subset of poor prognosis,
advanced-stage Hodgkin Lymphoma patients, defined as PET-positive after two courses of
conventional adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD)
chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Ospedale Santa Croce-Carle Cuneo
Collaborators:
Consorzio Mario Negri Sud GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)